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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.11.004OBJECTIVE: To investigate DBC2 mutations in breast cancer patients and evaluate the relationship between
gene mutations and breast cancer susceptibility in an Eastern China population.
METHODS: Mutation analyses of 285 bp promoter sequence, coding exon 7 and its exon/intron boundaries of
DBC2 were performed in 32 breast cancer specimens by polymerase chain reaction and direct sequencing.
Eighteen benign breast tumor specimens were also analyzed as control.
RESULTS: No mutation in the promoter or exon 7 was found in either group. An intronic alteration
(IVS7 + 53C > G) was detected in 13 specimens. There was no significant difference in the rate of
IVS7 + 53C > G alteration between the study and control groups (8/32 vs 5/18, respectively, P > 0.05). The G
allele of IVS7 + 53 was correlated with HER2 and p53 expression (P < 0.05), but not with age, tumor size,
lymph node metastasis, ER or PR expression (P > 0.05).
CONCLUSION: Mutation in the promoter and exon 7 of DBC2 gene is not common in the Chinese population
and may not contribute to the susceptibility for breast cancer in China. The intronic alteration IVS7 + 53C > G is
a common polymorphism in the Chinese Han ethnic group. Further research is warranted to evaluate the rela-
tionship between IVS7 + 53C > G and the susceptibility for breast cancer.1
s
HBreast cancer is one of the most commonmalignancies threatening women’s health.More than 234,580 new cases of breast cancer
will be diagnosed and 40,030 will die from the disease
in the United States in 2013.1 The incidence rate of
breast cancer in China was relatively lower before
1960s, but it has been increasing rapidly since
1970s. Data from Shanghai Disease Prevention and
Control Center shows that breast cancer has become
the most common malignancy and ranks ﬁrst among
the cause of cancer death in Shanghai since 2005.
Early stage breast cancer showed good outcomes.
However, for most patients who were diagnosed
with advanced cancer, the prognosis was veryGuoping Fu and Haixin Wang contributed equally to this
tudy.
ematol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.copoor. Therefore, it is crucial to ﬁnd new tumor
markers in order to screen breast cancer
susceptible population and improve the prognosis of
the disease.
DBC2 gene (deleted in breast cancer 2), also
known as RhoBTB2, was ﬁrst cloned from breast can-
cer tissues by Hamaguchi and colleagues.2 Research
shows that DBC2 participates in a variety of cellular
functions such as cell cycle control, apoptosis,
cytoskeleton regulation, and protein transport.3–5
The expression of DBC2 is frequently extinguished
in tumor tissues,2,6,7 and reintroduction of DBC2
gene can inhibit the growth, migration and invasion
of tumor cells.2,8,9 Therefore, DBC2 is thought to
play an important role in the carcinogenesis and
progression of breast cancer. However, as a newly
identiﬁed tumor suppressor gene, scant research on
DBC2 in breast cancer has been reported until now,
and even less so in China. In our study, we analyzedm 59
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the polymorphism in the promoter region and exon 7
of DBC2, as well as investigated whether the geno-
typic background contributes to the oncogenesis of
breast cancer in the Chinese Han ethnic group.MATERIALS AND METHODS
Study subjects
Thirty-two tumor samples from sporadic breast can-
cer patients were collected from Changhai Hospital.
All patients were female, from Eastern China and of
Han ethnicity, with negative family history of breast
cancer. The average onset age of the disease was
51.03 years with a range of 35–77. Eighteen benign
breast tumor samples were also analyzed as control.
The resected specimens were immediately frozen in li-
quid nitrogen and stored at 80 C until DNA
extraction. Pathological examination conﬁrmed the
diagnosis of breast cancer. ER, PR and HER2 status
were determined by immunohistochemistry testing,
and positive ER and PR status was deﬁned by nuclear
staining of more than 1%. For HER2, sample score as
3+ was classiﬁed as HER2-positive, or else assigned
to HER2-negative. Informed consent was obtained
from each individual recruited for this study, and
the study was approved by the Ethics Commission
of Second Military Medical University.
Polymerase chain reaction and DNA sequencing
Genomic DNA was extracted from tumor tissue
using QIAamp DNA Mini Kits, and stored at
20 C until ampliﬁcation. Primers were designed
by Primer 5.0 software using AF315385 as reference
sequence. Primer sequence for the promoter was:
50-CCGAAGGAAAGGGGAAAAC-30 (Forward),
and 50-CGCACCCAAGACGACAGC-30 (Reverse).
Primer sequence for exon 7 was: 50-CTGTCCGC
TCACTCCTTC-30 (Forward), and 50-GCAC-
CACCCTTCTTCACT-30 (Reverse). The speciﬁcity
of the primers was veriﬁed by blasting in GenBank
database, and synthesized by Shanghai Sangon
Biological Engineering Technology & Services Co.,
Ltd. PCR ampliﬁcation for both the promoter and
exon 7 was performed on the T-gradient thermocycler
(Whatman Biometra, Germany) in a ﬁnal volume of
60 lL. Reactions were performed as recommended
by the manufacturers using 35–40 cycles of
denaturation, annealing (at primer speciﬁc Ta) and
extension.
DNA sequencing was carried out using the PCR
primers and ABI 3730XL Genetic Analyzer auto-
mated sequencer (Applied Biosystems, Foster City,HemaCA). Any mutation-suspected sample was later con-
ﬁrmed by reverse sequencing.
Statistics
SPSS13.0 software was used to analyze the data. The
statistical methods included Fisher’s exact test and t-
test. P values <0.05 were considered statistically
signiﬁcant.RESULTS
Mutation analysis
Genomic variation was not found in either promoter
fragment or exon 7 of the DBC2 gene. An intronic
alteration (IVS7 + 53C > G) was detected in intron
7 in 13 specimens, including eight breast cancer sam-
ples and give breast benign tumor samples (Figure 1).
The frequency of the alteration in the research and
control groups was 25% (8/32) and 27.78% (5/18)
respectively. The difference was not statistically signif-
icant (P = 1.000).
Relationship between DBC2 alteration and
clinicopathological characteristics
In patients with breast cancer, the average onset age of
patients who carried the G allele of IVS7 + 53 was
51.13 ± 11.23 years. For the IVS7 + 53 wild-type pa-
tients, it was 51 ± 8.57 years. The difference was not
statistically signiﬁcant (P = 0.974). Expression of
HER2 and p53 was signiﬁcantly higher in patients
who carried the IVS7 + 53C > G variant than those
who carried the IVS7 + 53 wild-type DBC2
(P < 0.05). Other characteristics, including tumor
size, lymph node metastasis, ER and PR expression
were similar in the two groups (Table 1), indicating
that IVS7 + 53C > G alteration was correlated with
HER2 and p53 expression, but not with age, tumor
size, lymph node metastasis, or ER or PR expression.DISCUSSION
The DBC2 gene, located in chromosome 8p21, is a
newly identiﬁed tumor suppressor gene.2 Regulated
by E2F1, DBC2 plays a key role in inducing cell
apoptosis and inhibiting tumor growth, migration
and invasion through interaction with CCND1,
BRMS1 and Cul3 ubiquitin ligase complexes.3,8,10–12
DBC2 mutation is correlated to the oncogenesis and
development of a variety of malignant tumors, includ-
ing breast, gastric and bladder cancers.2,6,7,13–15
Recently, Ohadi et al. reported two mutation sites
(238G > A and 121C > T) in DBC2 promotertol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.com
Figure 1. Mutation detection in intron 7 of DBC2 gene. DNA sequencing reveals a IVS7 + 53C > G polymorphism (variant, arrowed).
Table 1. Correlation of DBC2 IVS7 + 53C > G mutation and clinico-
pathological characteristics of breast cancer (n = 32).
Variable n IVS7 + 55C > G P valuef
Yes No
Tumor size
T1 + T2 31 8 23 1.000
T3 + T4 1 0 1
Lymph nodes
+ 17 3 14 0.423
 15 5 10
ER
+ 20 6 14 0.676
 12 2 10
PR
+ 18 6 12 0.412
 14 2 12
HER2
+ 6 4 2 0.023
 26 4 22
p53
+ 16 7 9 0.037
 16 1 15
f = Fisher's exact test.
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for the transcription factors Sp1-1 and E2F, respec-
tively.13 Knowles et al discovered a missense mutation
(1681G > A, causing protein 561G > S) in DBC2 7
exon in a bladder cancer sample.15 Both the deletionHematol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.coof transcription factor binding site and missense muta-
tion could alter gene expression. In our study, we con-
ducted gene mutation analysis in the promoter and
exon 7 of DBC2 gene to conﬁrm its role in breast
cancer.
However, similar results were not repeated in our
study. No mutation was found in DBC2 promoter
or exon 7 in patients with breast cancer. Possible
explanations for the discrepancy could be: (1) The
samples obtained in our study were from the Han eth-
nic group. There might be differences in genetic pre-
disposition between Han ethnicity and European or
Middle-Eastern populations in the Knowles and Oha-
di studies; (2) DBC2 was found to participate in a vari-
ety of cellular functions such as cell cycle control,
apoptosis, cytoskeleton regulation, and protein trans-
port. However, despite the fact that mutation in exon
7 is found in bladder cancer, whether exon 7 mutation
in DBC2 plays a role in the carcinogenesis and pro-
gression of breast cancer is still not clear. Genomic
sites other than promoters and exon 7 could be of
interest for future investigation. In addition, since
the frequency of the mutation in both the Ohadi and
Knowles studies is low (less than 1%), our study sam-
pling might not be big enough to detect the mutation.
In our study, we detected 13 cases with
IVS7 + 53C > G variant, including eight cases of
malignant tumor and ﬁve cases of benign tumor.
The frequency of IVS7 + 53C > G in the research
and control groups was 25% (8/32) and 27.78% (5/
18), respectively. The difference between the two
groups was not statistically signiﬁcant. By analyzing
the correlation of IVS7 + 53C > G alteration and
clinicopathological factors, we found the G allele of
IVS7 + 53 to be correlated with HER2 and p53
expression (P < 0.05), but not with patient age, tu-
mor size, lymph node metastasis, or ER or PR expres-
sion (P > 0.05). Both HER2 and p53 mutations have
the potential activity of promoting carcinogenicity.
In summary, mutation in the promoter and exon 7
of DBC2 may not contribute to the susceptibility form 61
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breast cancer in our region. Intronic variation
IVS7 + 53C > G was a common polymorphism in
the Chinese Han ethnicity. Further study on a larger
population is warranted to investigate whether
IVS7 + 53C > G is an independent risk factor for
breast cancer.
Previous studies showed that variation in DBC2
expression is very frequent, while the gene mutation
is rather infrequent,2,7,16 indicating that epigenetic
events may play a much more important role in the
loss of DBC2 expression. Recently, Shi and colleagues
analyzed promoter methylation and DBC2 gene
expression by MS-PCR and RT-PCR in a research
study on bladder cancer. They reported that the fre-
quency of methylation in DBC2 promoter was signif-
icantly higher in bladder tumor samples than that of
corresponding normal tissues, and hyper-methylation
was highly correlated to the gene inactivation. They
speculated that DBC2 inactivation by hyper-methylationHemamay be a crucial step in the process of cell carcinoge-
nicity. Therefore, research on hyper-methylation at
CpG Island may be a new way for revealing the rela-
tionship between the inactivation of DBC2 and sus-
ceptibility for breast cancer, hence providing a novel
molecular target for diagnosis, treatment and progno-
sis of the disease.CONFLICT OF INTEREST
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